Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

24.45USD
16 Aug 2018
Change (% chg)

$-0.35 (-1.41%)
Prev Close
$24.80
Open
$24.95
Day's High
$24.95
Day's Low
$24.30
Volume
114,450
Avg. Vol
158,295
52-wk High
$26.08
52-wk Low
$11.93

Chart for

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $661.66
Shares Outstanding(Mil.): 35.29
Dividend: --
Yield (%): --

Financials

  AMAG.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.39 -- --
ROI: -2.17 15.07 14.61
ROE: -4.83 16.59 16.33

BRIEF-AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59

* AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RAISES FULL YEAR FINANCIAL GUIDANCE

03 May 2018

BRIEF-AMAG Pharmaceuticals Appoints J. Alan Butcher As Executive Vice President

* AMAG PHARMACEUTICALS APPOINTS J. ALAN BUTCHER AS EXECUTIVE VICE PRESIDENT AND CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide

* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal

* AMAG PHARMACEUTICALS - ‍CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION​

23 Mar 2018

BRIEF-AMAG Reports Q4 Earnings Of $0.10 Per Share

* TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION

27 Feb 2018

Earnings vs. Estimates